AstraZeneca Gets FDA Approval for Ovarian Cancer Drug
20 December 2014 - 8:09AM
Dow Jones News
By Tapan Panchal
LONDON--Pharmaceutical company AstraZeneca PLC (AZN.LN) on
Friday said the U.S. Food and Drug Administration has approved
Lynparza for the treatment of advanced ovarian cancer.
The regulator has approved 400 milligrams capsules of Lynparza
as the first monotherapy for patients with advanced ovarian cancer,
who have been treated with three or more prior lines of
chemotherapy.
Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024